SciELO - Scientific Electronic Library Online

vol.36 issue 1A preventable disease: stroke in non-valvular atrial fibrillation. What is the role of the new oral anticoagulants?Paraneoplastic Vasculitis: Presentation of two clinical cases author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links


Archivos de Medicina Interna

Print version ISSN 0250-3816On-line version ISSN 1688-423X


VALVERDE, Marcelo et al. Hepatorenal Syndrome: clinical approach and therapeutic strategy. Arch. Med Int [online]. 2014, vol.36, n. 1, pp.17-27. ISSN 0250-3816.

Hepatorenal syndrome (HRS) is defined as the onset of renal failure without an identifiable cause in a cirrhotic patient. According with the installation speed and the severity of the renal failure, two types are described: type I and type II. Type I is characterized by a rapid and progressive deterioration of renal function with an ominous prognosis. Type II, presents with an insidious and less severe development of renal failure, but always bears a poor short-term prognosis. Although the implementation of therapeutic strategies has a clear impact on the prognosis, the median overall survival of these patients is approximately 3 months (2 weeks for type I HRS vs. 4 to 6 months for type II HRS). Since there are no specific tests for the diagnosis, it is based on a combination of clinical and laboratory data as well as the exclusion of other kinds of renal injury. Systemic vasoconstrictors drugs analogues of vasopressin combined with albumin are the treatment of choice before liver transplantation, which constitutes the definitive treatment of this entity.

Keywords : Hepatorenal syndrome; Renal failure; Cirrhosis.

        · abstract in Spanish     · text in Spanish


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License